Panel: The Impact of Universal Donor Cells and iPSCs on the Cell Therapy Industry
Автор: Alliance for Regenerative Medicine
Загружено: 2019-10-18
Просмотров: 1668
Описание:
Since the discovery of pluripotent stem cells in the early 1980’s, the promise of fit-to-purpose cell replacement therapy has occupied the imaginations of many in the medical and patient communities. Progress was slowed by both technical and ethical challenges, but with the discovery of the iPSC source in 2006, many of these hurdles were overcome and the pace of research and clinical development accelerated dramatically. Further, genetic and biomaterials modification to this limitless supply of cells has opened new doors to allogeneic stem cell-derived cell therapy, including the associated promise of lower costs and higher accessibility. This panel will explore the ways in which iPSCs, and more specifically iPSCs modified for allogeneic use, have changed the way in which we think about the commercial viability of cell therapies.
Chair:
Robert Preti, Ph.D., President and CEO, Hitachi Chemical Advanced Therapeutics Solutions; GM, Hitachi Chemical Regenerative Medicine Business Sector
Speakers:
Stewart Abbot, Ph.D., Chief Operating and Scientific Officer, Adicet Bio
Usman Azam, M.D., President and CEO, Tmunity Therapeutics
Tim Lu, M.D., Ph.D., Co-Founder and CEO, Senti Biosciences
Bastiano Sanna, Ph.D., CEO, Semma Therapeutics
Dan Shoemaker, Ph.D., Chief Scientific Officer, Fate Therapeutics
Повторяем попытку...
Доступные форматы для скачивания:
Скачать видео
-
Информация по загрузке:
